Flu virus changes every year, and that’s why yearly vaccination is the most effective way to help prevent flu and its complications.

The FLU SV MRNA-028 study is testing a new mRNA-based vaccine designed to protect against multiple flu virus strains, including those that may differ from the predicted strains.

This study will evaluate whether the investigational vaccine provides sufficient or better protection against seasonal flu compared to current vaccines, for participants who are more than 18 years of age.

Our vaccine aims to enhance the immune system’s ability to recognize and fight off multiple flu virus strains. This may reduce the severity of the illness and provide better defence, even when the vaccine isn’t an exact match for the flu strains circulating in a particular year.

If you are 18 years of age or older and would like to learn more about this study, please speak to your doctor.

Taking part in a clinical trial is voluntary. You are free to leave at any time and do not need to provide a reason.

Flu virus changes every year, and that's why yearly vaccination is the most effective way to help prevent flu and its complications.

In this study, we will be working together to see if an investigational medicine is safe to use, and whether it can help people with overweight or obesity to lose weight and manage weight-related conditions. The investigational medicine is a monthly injection that is given subcutaneously (under the skin). Increasing physical activity and reducing the number of calories eaten does not necessarily lead to a reduction in weight for all individuals. As obesity continues to increase, this is a concern, as some diseases are known to occur more often in people with overweight or obesity.

Researchers are testing an investigational medicine for COVID-19. They want to know how well it may work and if it is safe in adults with COVID-19 who are at a higher risk for severe illness from COVID-19.

Join a clinical study testing the effects of an investigational oral drug on blood pressure.

To be eligible for the study, you must be diagnosed with RSV and enrolled within 3 days of your symptoms starting.

Study to Evaluate the Efficacy, Safety and Tolerability of Balcinrenone in Combination with Dapagliflozin Compared with Dapagliflozin in Patients with Chronic Kidney Disease and Albuminuria.